Ivor Elrifi
Vermögen: 4 Mio $ am 31.05.2026
Vermögen: 4 Mio $ am 31.05.2026
Ivor Elrifi is Chief Executive Officer & Executive Director at Tiziana Life Sciences Ltd. since 2024.
Formerly, Dr. Elrifi was Global Head-Patent at Cooley LLP from 2014 to 2024 and Global Head-Patents at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC from 1999 to 2014.
Education includes undergraduate and doctorate degrees from Queen's University and a graduate degree from Osgoode Hall Law School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 2 687 248 ( 2,26 % ) | 4 Mio $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| TIZIANA LIFE SCIENCES LTD | Vorstandsvorsitzender | 19.08.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01.08.2024 |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01.01.2014 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Queen's University
Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cooley LLP
Cooley LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Osgoode Hall Law School
Osgoode Hall Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen